33
Participants
Start Date
June 30, 2002
Primary Completion Date
June 30, 2003
Study Completion Date
June 30, 2003
semapimod
semapipmod 60 mg IV x 5 days
semapimod
IV 30 mg x 5 days
placebo
placebo IV
Long Island Clinical Research Associates, Great Neck
Regional Gastroenterology Associates of Lancaster, Ltd., Lancaster
Digestive and Liver Disease Specialists, Norfolk
Wake Research Associates, Raleigh
Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Atlanta Gastroenterology Associates, Atlanta
Institute of Healthcare Assessment, San Diego
University of Florida, Gainesville
Northwestern University, Chicago
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Mount Sinai School of Medicine, New York
Oklahoma Foundation for Digestive Research, Oklahoma City
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY